Edgewise Therapeutics, Inc. EWTX
37.67 USD -0.44 (-1.16%)
Nov 3, 2026, 3:45 PM EST
36.70 Day range 40.41
16.70 52-week range 48.51
- YTD
- +51.77%
- 1 year
- +109.62%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 54.00 +43.4% upside
Now 37.67
- Target (low)
- 36.00
- Target (mean)
- 54.00
- Target (high)
- 66.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy3
- Buy9
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.51 | -0.64 – 11.45 | -0.39 | +744.4% | 0 | 0.0% | 11 |
| Next quarter | -0.46845 | -0.78 – -0.13 | -0.47 | +0.3% | 0 | 0.0% | 12 |
| Current year | 2.27 | -2.42 – 11.22 | -1.63 | +239.6% | 0 | 0.0% | 11 |
| Next year | -1.87 | -3.44 – -0.47 | 2.27 | -182.2% | 31.36M | 0.0% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | William Blair | Initiated | — | Outperform |
| Sep 21, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 20, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 11, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Jul 20, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jul 9, 2026 | Oppenheimer | Initiated | — | Outperform |
| Jul 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jun 17, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jun 17, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Jun 16, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 2, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jun 2, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 17, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 17, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 27, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Nov 14, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 7, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 7, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Sep 25, 2025 | Goldman Sachs | Initiated | — | Neutral |
| Aug 19, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 8, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Jun 30, 2025 | HC Wainwright & Co. | Initiated | — | Buy |
| Jun 5, 2025 | RBC Capital | Reiterated | Outperform | Outperform |
| May 16, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| May 9, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 21, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Apr 3, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 3, 2025 | Scotiabank | Downgrade | Sector Outperform | Sector Perform |
| Apr 2, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
